All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your PsOPsA Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Visual abstract | COMFORT-1 trial: Piclidenson for plaque psoriasis

Mar 25, 2024
Learning objective: fter reading this article, learners will be able to cite a new development in psoriasis.

Bookmark this article

The Psoriasis and Psoriatic Arthritis Hub is pleased to present a visual abstract summarizing results from the phase III, multicenter COMFORT-1 trial (NCT03168256) evaluating the safety and efficacy of piclidenoson (2 mg and 3 mg) compared with apremilast and placebo.1 

Piclidenoson, an A3 adenosine receptor agonist, down-regulates the NF-kB signaling pathway, inducing an anti-inflammatory effect.1 A3 adenosine receptor agonists are highly expressed in the skin of patients with psoriasis, and previous phase II studies have demonstrated the clinical benefit of piclidenoson versus placebo. In this phase III study by Papp et al., piclidenoson was well tolerated up to 32 weeks.1 

Visual Abstract

Click here to download this visual abstract


  1. Papp KA, Beyska-Rizova S, Gantcheva ML, et al. Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT-1). J Eur Acad Dermatol Venereol. 2024. Online ahead of print. DOI: 1111/jdv.19811


Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox